tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

NMRA Stock Latest News

Neumora initiates Phase 2 study of navacaprant in bipolar depression
The FlyNeumora initiates Phase 2 study of navacaprant in bipolar depression
4d ago
NMRA
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
PremiumPress Releases
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
4d ago
NMRA
Neumora Therapeutics reports Q1 EPS (34c), consensus (34c)
PremiumThe Fly
Neumora Therapeutics reports Q1 EPS (34c), consensus (34c)
11d ago
NMRA
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
PremiumPress Releases
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
11d ago
NMRA
Neumora Therapeutics falls 23% after FDA clinical hold of Phase 1 NMRA-266 study
PremiumThe Fly
Neumora Therapeutics falls 23% after FDA clinical hold of Phase 1 NMRA-266 study
1M ago
NMRA
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
PremiumPress ReleasesNeumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
1M ago
NMRA
Neumora Therapeutics announces clinical hold of Phase 1 NMRA-266 study
PremiumThe Fly
Neumora Therapeutics announces clinical hold of Phase 1 NMRA-266 study
1M ago
NMRA
Neumora weakness amid lock-up expiration a buying opportunity, says RBC Capital
PremiumThe Fly
Neumora weakness amid lock-up expiration a buying opportunity, says RBC Capital
2M ago
NMRA
Neumora weakness amid lock-up expiration a buying opportunity, says RBC Capital
PremiumThe Fly
Neumora weakness amid lock-up expiration a buying opportunity, says RBC Capital
2M ago
NMRA
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
PremiumPress Releases
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
2M ago
NMRA
Neumora Therapeutics price target raised to $31 from $24 at RBC Capital
PremiumThe Fly
Neumora Therapeutics price target raised to $31 from $24 at RBC Capital
2M ago
JNJ
NMRA
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
PremiumPress Releases
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2M ago
NMRA
Neumora Therapeutics reports Q4 EPS (71c), consensus (55c)
PremiumThe FlyNeumora Therapeutics reports Q4 EPS (71c), consensus (55c)
2M ago
NMRA
JPMorgan biotech analysts to hold an analyst/industry conference call
PremiumThe Fly
JPMorgan biotech analysts to hold an analyst/industry conference call
3M ago
BHVN
ITCI
JPMorgan biotech analysts to hold an analyst/industry conference call
PremiumThe Fly
JPMorgan biotech analysts to hold an analyst/industry conference call
3M ago
BHVN
ITCI
Neumora Therapeutics appoints Panandiker as Chief Commercial Officer
PremiumThe Fly
Neumora Therapeutics appoints Panandiker as Chief Commercial Officer
4M ago
CERE
NMRA
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
PremiumPress Releases
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
4M ago
NMRA
The biopharmaceuticals stocks to own in 2024, according to BofA
PremiumThe Fly
The biopharmaceuticals stocks to own in 2024, according to BofA
5M ago
BMY
JNJ
Neumora Therapeutics price target raised to $20 from $18 at BofA
PremiumThe Fly
Neumora Therapeutics price target raised to $20 from $18 at BofA
5M ago
JNJ
NMRA
Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
PremiumPress ReleasesNeumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
5M ago
NMRA
Neumora Therapeutics appoints Jason Duncan as CLO
PremiumThe Fly
Neumora Therapeutics appoints Jason Duncan as CLO
5M ago
NMRA
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
PremiumPress Releases
Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer
5M ago
NMRA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >